Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.
London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. London WB, et al. Among authors: pearson ad. J Clin Oncol. 2011 Aug 20;29(24):3286-92. doi: 10.1200/JCO.2010.34.3392. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768459 Free PMC article.
Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.
Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F. Ladenstein R, et al. J Clin Oncol. 1998 Mar;16(3):953-65. doi: 10.1200/JCO.1998.16.3.953. J Clin Oncol. 1998. PMID: 9508178
Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
Burchill SA, Lewis IJ, Abrams KR, Riley R, Imeson J, Pearson AD, Pinkerton R, Selby P. Burchill SA, et al. Among authors: pearson ad. J Clin Oncol. 2001 Mar 15;19(6):1795-801. doi: 10.1200/JCO.2001.19.6.1795. J Clin Oncol. 2001. PMID: 11251011
Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors.
Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, Mazzocco K, Roberts P, Nicholson J, Ellershaw C, Pearson AD, Jackson MS; United Kingdom Children Cancer Study Group and the United Kingdom Cancer Cytogenetics Group. Lastowska M, et al. Among authors: pearson ad. J Clin Oncol. 2001 Jun 15;19(12):3080-90. doi: 10.1200/JCO.2001.19.12.3080. J Clin Oncol. 2001. PMID: 11408505
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL; International Neuroblastoma Risk Group. Bagatell R, et al. Among authors: pearson ad. J Clin Oncol. 2009 Jan 20;27(3):365-70. doi: 10.1200/JCO.2008.17.9184. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047282 Free PMC article.
The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD; INRG Task Force. Monclair T, et al. Among authors: pearson ad. J Clin Oncol. 2009 Jan 10;27(2):298-303. doi: 10.1200/JCO.2008.16.6876. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047290 Free PMC article.
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. Cohn SL, et al. Among authors: pearson ad. J Clin Oncol. 2009 Jan 10;27(2):289-97. doi: 10.1200/JCO.2008.16.6785. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047291 Free PMC article.
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.
De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD. De Bernardi B, et al. Among authors: pearson ad. J Clin Oncol. 2009 Mar 1;27(7):1034-40. doi: 10.1200/JCO.2008.17.5877. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171711 Clinical Trial.
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.
Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Köhler G, Leuschner I, Pearson AD, Lunec J, Tweddle DA. Carr-Wilkinson J, et al. Among authors: pearson ad. Clin Cancer Res. 2010 Feb 15;16(4):1108-18. doi: 10.1158/1078-0432.CCR-09-1865. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145180 Free PMC article.
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project.
Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Moroz V, et al. Among authors: pearson ad. Eur J Cancer. 2011 Mar;47(4):561-71. doi: 10.1016/j.ejca.2010.10.022. Epub 2010 Nov 26. Eur J Cancer. 2011. PMID: 21112770
399 results